Revance Therapeutics (RVNC) Expected to Announce Quarterly Earnings on Wednesday

Revance Therapeutics (NASDAQ:RVNC) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $78.12 million for the quarter.

Revance Therapeutics Stock Performance

Revance Therapeutics stock opened at $3.65 on Tuesday. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.56. The firm’s fifty day simple moving average is $3.42 and its 200-day simple moving average is $4.60. The company has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on RVNC shares. Mizuho cut their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. HC Wainwright restated a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. StockNews.com began coverage on Revance Therapeutics in a report on Saturday. They set a “hold” rating on the stock. Finally, Barclays dropped their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.